Actionable Stock Market Trading Newswire. Built for Traders, by Traders.
All news is property of their respective owners.

BTIG Downgrades Taysha Gene Therapies to Neutral

BTIG analyst Yun Zhong downgrades Taysha Gene Therapies (NASDAQ:TSHA) from Buy to Neutral.

byBenzinga Newsdesk

February 2, 2023

1 minute read

BTIG analyst Yun Zhong downgrades Taysha Gene Therapies (NASDAQ:TSHA) from Buy to Neutral.

Avicanna Closes $2M Non-Brokered Private Placement

By Javier Hasse

Today, 12:43 PM

Avicanna Inc. (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN), a commercial-stage, international biopharmaceutical company focused on the development advancement and commercialization of cannabinoid-based products, has closed a non-brokered private placement offering of 7,210,194 ‎‎units at a p

AVCNF

Keybanc Maintains Overweight on BigCommerce Holdings, Lowers Price Target to $30

By Benzinga Newsdesk

Today, 12:43 PM

Keybanc analyst Josh Beck maintains BigCommerce Holdings (NASDAQ:BIGC) with a Overweight and lowers the price target from $40 to $30.

BIGC

Endeavour Silver Q2 Sales $47.77M Beat $38.33M Estimate

By Benzinga Newsdesk

Today, 12:43 PM

Endeavour Silver (NYSE:EXK) reported quarterly sales of $47.77 million which beat the analyst consensus estimate of $38.33 million by 24.64 percent. This is a 136.50 percent increase over sales of $20.20 million the

EXK